Erlotinib News and Research

RSS
Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva.
New blood test can accurately, quickly identify genetic mutations linked to NSCLC

New blood test can accurately, quickly identify genetic mutations linked to NSCLC

Researchers propose novel theory of how some cancers circumvent killing power of targeted therapies

Researchers propose novel theory of how some cancers circumvent killing power of targeted therapies

Penn studies provide new understanding of lung cancer progression and prevention

Penn studies provide new understanding of lung cancer progression and prevention

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Added benefit of lung cancer drug not proven, says IQWiG

Added benefit of lung cancer drug not proven, says IQWiG

FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

Study assesses effect of chemoradiotherapy on survival of locally advanced pancreatic cancer patients

Study assesses effect of chemoradiotherapy on survival of locally advanced pancreatic cancer patients

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

New study describes a way to identify complex type of mutation in cancer genomes

New study describes a way to identify complex type of mutation in cancer genomes

Post-progression afatinib exposure boosts NSCLC outcomes

Post-progression afatinib exposure boosts NSCLC outcomes

New tool could help identify patients most likely to benefit from chemoprevention

New tool could help identify patients most likely to benefit from chemoprevention

Early trial results in lung cancer

Early trial results in lung cancer

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BGB324 shows enhanced tumour clearance in mouse carcinoma models

AstraZeneca presents lung cancer research data at WCLC 2015

AstraZeneca presents lung cancer research data at WCLC 2015

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

LUX-Lung 8 supports afatinib in squamous NSCLC

LUX-Lung 8 supports afatinib in squamous NSCLC

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015